Literature DB >> 18559927

Sequence-specific cleavage of hepatitis C virus RNA by DNAzymes: inhibition of viral RNA translation and replication.

Swagata Roy1, Nidhi Gupta2, Nithya Subramanian1, Tanmoy Mondal1, Akhil Chandra Banerjea2, Saumitra Das1.   

Abstract

DNAzyme (Dz) molecules have been shown to be highly efficient inhibitors of virus replication. Hepatitis C virus RNA translation is mediated by an internal ribosome entry site (IRES) element located mostly in the 5' untranslated region (UTR), the mechanism of which is fundamentally different from cap-dependent translation of cellular mRNAs, and thus an attractive target for designing antiviral drugs. Inhibition of HCV IRES-mediated translation has drastic consequences for the replication of viral RNA as well. We have designed several Dzs, targeting different regions of HCV IRES specific for 1b and also sequences conserved across genotypes. The RNA cleavage and translation inhibitory activities of these molecules were tested in a cell-free system and in cell culture using transient transfections. The majority of Dzs efficiently inhibited HCV IRES-mediated translation. However, these Dz molecules did not show significant inhibition of coxsackievirus B3 IRES-mediated translation or cap-dependent translation of reporter gene, showing high level of specificity towards target RNA. Also, Northern blot hybridization analysis showed significant cleavage of HCV IRES by the Dz molecules in Huh7 cells transiently transfected with the HCV-FLuc monocistronic construct. Interestingly, one of the Dzs was more effective against genotype1b, whereas the other showed significant inhibition of viral RNA replication in Huh7 cells harbouring a HCV 2a monocistronic replicon. As expected, mutant-Dz failed to cleave RNA and inhibit HCV RNA translation, showing the specificity of inhibition. Taken together, these findings suggest that the Dz molecule can be used as selective and effective inhibitor of HCV RNA replication, which can be explored further for development of a potent therapeutic agent against HCV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559927     DOI: 10.1099/vir.0.83650-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Tailoring the switch from IRES-dependent to 5'-end-dependent translation with the RNase P ribozyme.

Authors:  Noemi Fernández; Encarnación Martínez-Salas
Journal:  RNA       Date:  2010-03-01       Impact factor: 4.942

2.  Inhibition of HIV-1 Integrase gene expression by 10-23 DNAzyme.

Authors:  Nirpendra Singh; Atul Ranjan; Souvik Sur; Ramesh Chandra; Vibha Tandon
Journal:  J Biosci       Date:  2012-07       Impact factor: 1.826

3.  Inhibition of the interaction between NS3 protease and HCV IRES with a small peptide: a novel therapeutic strategy.

Authors:  Upasana Ray; Chaitrali L Roy; Anuj Kumar; Prashant Mani; Agnel P Joseph; G Sudha; Debi P Sarkar; N Srinivasan; Saumitra Das
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

Review 4.  HCV drug discovery aimed at viral eradication.

Authors:  R F Schinazi; L Bassit; C Gavegnano
Journal:  J Viral Hepat       Date:  2009-12-18       Impact factor: 3.728

Review 5.  Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site.

Authors:  Sergey M Dibrov; Jerod Parsons; Maia Carnevali; Shu Zhou; Kevin D Rynearson; Kejia Ding; Emily Garcia Sega; Nicholas D Brunn; Mark A Boerneke; Maria P Castaldi; Thomas Hermann
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

Review 6.  Prospects for nucleic acid-based therapeutics against hepatitis C virus.

Authors:  Chang Ho Lee; Ji Hyun Kim; Seong-Wook Lee
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

Review 7.  Exploring Internal Ribosome Entry Sites as Therapeutic Targets.

Authors:  Anton A Komar; Maria Hatzoglou
Journal:  Front Oncol       Date:  2015-10-20       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.